Monsoon gut ailments push gastro medicine sales up 11% in August

Demand for medicines used for common gastrointestinal complaints rose during the rainy season, with the gastrointestinal therapy segment growing 11% in August, according to research firm Pharmatrack. Antacid sales rose 11%, laxatives 14% and probiotics 17%. The vitamins, minerals and nutrients segment grew 16%, anti-diabetics 15% and cardiac therapies 15%, while anti-infectives grew only 3%. Doctors said sales data alone cannot confirm a disease surge and warned against repeated self-medication.

Written by AI from News18 — India · not yet reviewed by an editor · Published 18 Sept 2026, 3:08 am IST

Source

News18 — India · read the original report ↗

#monsoon#gastrointestinal#pharma sales#self-medication#public health

Desk check · compared with the source

What the desk checked (5)

Gastrointestinal therapy segment grew 11% in August, with antacids up 11%, laxatives 14% and probiotics 17%. — Figures appear in source, attributed to research firm Pharmatrack.
Vitamins, minerals and nutrients segment grew 16% in August. — Figure appears in source, attributed to the same sales data.
Anti-diabetic segment grew 15%, with tirzepatide the fastest-growing molecule; cardiac therapies also grew 15%. — Figures appear in source; attributed to the data, no independent verification possible.
Anti-infectives grew only about 3%, possibly due to restrictions on over-the-counter antibiotic sales. — Figure in source; interpretation attributed to Dr Rajeev Jayadevan as a possibility, not established fact.
Sales data alone cannot confirm a surge in gastrointestinal disease. — Attributed caveat from Dr Jayadevan, citing prescription-free purchases in India.

Written by AI from News18 — India · not yet reviewed by an editor · How we use AI · Report an error

Analysts’ view opinion

AI Policy Analyst

Read as a policy signal rather than a health bulletin, this data says less about how sick India got in August and more about how Indians buy medicine — largely over the counter, often without clinical evaluation. The most policy-relevant number is the one that barely moved: 3% growth in anti-infectives against 11% for gastrointestinal drugs, which one of the doctors quoted links to tighter prescription-only enforcement at pharmacies. That contrast suggests regulation can bend behaviour where it is actually enforced, and that the unregulated end of the shelf — antacids, laxatives, PPIs, supplements — is where governance is thinnest.

Sales data is a commercial dataset, not surveillance: using it as a proxy for disease burden confuses market demand with epidemiology, and the story's own experts flag that gap.
The modest 3% anti-infective growth is the clearest evidence in this story that antibiotic-dispensing curbs are having some effect, while categories outside prescription control grew far faster.
Monsoon gut illness is substantially a water, sanitation and food-safety problem, so a demand spike met mainly by retail pharmacy purchases points to prevention gaps upstream of the health system.
Doctors' warning on self-medication is a design problem, not just a patient-behaviour problem: when oral rehydration and hydration would suffice, easy OTC access can substitute pharmaceuticals for basic care and mask warning signs.
Strong growth in anti-diabetic (15%), cardiac (15%) and VMN (16%) categories reflects chronic-disease and wellness spending trends that raise separate questions about out-of-pocket cost and prescribing norms.

What to watch — Watch whether prescription-only enforcement at pharmacies is extended beyond antibiotics to habitually over-used categories like PPIs, and whether monsoon-season public messaging shifts toward ORS, water safety and food hygiene rather than pharmacy-led relief.

The story does not establish that gastrointestinal disease actually rose in August, nor does it quantify how much of the sales growth came from prescriptions versus self-medication, price changes or stocking patterns.

Deep dive

Research brief · 8 facts · 3 dates · exam-ready

The brief

Context

Every monsoon, waterborne and foodborne illnesses such as diarrhoea, gastroenteritis, acidity and indigestion rise in India, pushing people to pharmacies for over-the-counter relief. Data from research firm Pharmatrack (Pharmarack) show the gastrointestinal (GI) therapy segment grew 11% in August, with antacids, laxatives and probiotics all recording higher sales. Doctors quoted in the story agree the monsoon changes the disease burden, but caution that pharmaceutical sales alone cannot prove a disease surge, since many medicines in India are bought without a prescription. They also warn against repeated self-medication when symptoms persist or come with warning signs.

Key facts

Gastrointestinal therapy segment sales grew 11% in August, according to Pharmatrack data.
Within the GI segment: antacid sales rose 11%, laxatives 14% and probiotics 17%.
The vitamins, minerals and nutrients (VMN) segment grew 16% in August.
The anti-diabetic segment grew 15%, supported by expansion of the GLP-1 agonist category, with tirzepatide the fastest-growing molecule.
Cardiac therapies grew 15%, driven by heart failure therapies, platelet aggregation inhibitors, lipid-lowering drugs, antithrombotic agents and fibrinolytics.
Anti-infectives grew only about 3%, far below the 11% growth in gastrointestinal medicines.
Sheetal Saple, vice president at Pharmarack, said gastro is an acute category whose sales pick up from the monsoon and current sales are in line with the long-term linear trend.
Dr Rajeev Jayadevan said PPIs are often prescribed for non-specific gastrointestinal complaints, making sales data hard to interpret as a disease surge.

Timeline

Monsoon season (rainy months)Doctors report increased hospital presentations of diarrhoea, gastroenteritis, acidity, indigestion and altered bowel habits.
AugustPharmatrack data record 11% growth in GI therapies, 16% in VMN, 15% each in anti-diabetics and cardiac therapies, and 3% in anti-infectives.
September 18, 2026, 02:35 ISTStory first published reporting the monsoon-linked rise in gastro medicine sales.

Who has a stake

Patients and consumers — Face seasonal gut ailments and risk of masking serious disease through repeated over-the-counter self-medication.
Pharmaceutical companies and pharmacies — Benefit from seasonal spikes in antacids, laxatives, probiotics and oral rehydration products; also gatekeepers of prescription-only drugs.
Doctors and gastroenterologists (Dr Mahendra Singh Rajput, Amrita Hospital, Faridabad; Dr Rajeev Jayadevan, Kerala) — Manage rising monsoon caseloads and must counsel patients against unnecessary self-medication.
Pharmarack / Pharmatrack (research firm) — Supplies the sales data that shapes public and industry reading of seasonal disease trends.
Drug regulators and antibiotic stewardship efforts — The modest 3% anti-infective growth is linked by a doctor to restrictions on over-the-counter antibiotic sales.

Why it matters

The seasonal jump in gut medicine sales is a proxy signal of India's monsoon burden of water- and food-borne illness, driven by contaminated water, unsafe food storage and high humidity. But because many Indians buy medicines without a doctor's evaluation, the same numbers also expose the risks of self-medication and over-prescription, such as routine use of PPIs for vague complaints. The comparatively low 3% growth in anti-infectives suggests tighter antibiotic dispensing may be having some effect on stewardship.

UPSC angle

Prelims pointers

Pharmatrack/Pharmarack data: GI therapy segment grew 11% in August; probiotics 17%, laxatives 14%, antacids 11%.
VMN (vitamins, minerals and nutrients) segment growth in August: 16%.
Anti-diabetics grew 15%, led by GLP-1 agonists; tirzepatide was the fastest-growing molecule.
Cardiac therapies grew 15%; anti-infectives grew only about 3%.
PPIs (proton pump inhibitors) are often prescribed for non-specific gastrointestinal complaints.
Most minor monsoon diarrhoeal illnesses are self-limiting and manageable with fluids and oral rehydration.

Mains framing

The 11% August rise in gastrointestinal medicine sales illustrates how India's monsoon reshapes the disease burden: high humidity, contaminated water, unsafe food storage and microbial growth create ideal conditions for water- and food-borne illness, producing more cases of diarrhoea, gastroenteritis, acidity and indigestion. Yet, as one gastroenterologist notes, sales figures are an imperfect epidemiological proxy because a large share of Indian medicine purchases happen directly at pharmacies without medical evaluation, and prescribing habits (for instance, PPIs for non-specific complaints) inflate volumes independently of actual illness. The parallel 16% growth in vitamins and supplements reflects both post-infection recovery use and rising preventive-health awareness, while the muted 3% growth in anti-infectives is read as a sign that curbs on over-the-counter antibiotic dispensing are working. The way forward, on the evidence in the story, lies in safe water and food handling during the rains, promoting oral rehydration for self-limiting diarrhoea, discouraging habitual over-the-counter treatment, and seeking medical care when there is persistent acidity, recurrent diarrhoea, blood in stools, fever, dehydration or severe abdominal pain.

Key terms

Gastrointestinal (GI) therapy segment: Pharma category covering medicines for gut complaints such as antacids, laxatives, probiotics and oral rehydration products.
PPIs (proton pump inhibitors): Acid-suppressing drugs that, per the story, are often prescribed for non-specific gastrointestinal complaints.
Probiotics: Products containing beneficial microorganisms used for gut health; sales rose 17% in August.
VMN segment: Vitamins, minerals and nutrients category of medicines/supplements, which grew 16% in August.
GLP-1 agonists: Class of anti-diabetic drugs whose expansion drove 15% growth in the segment; tirzepatide was the fastest-growing molecule.
Anti-infectives: Drugs including antibiotics that fight infections; grew only about 3%, linked to curbs on over-the-counter antibiotic sales.

Practice questions

Monsoon conditions in India raise the burden of water- and food-borne illness. Discuss the public health measures needed to reduce seasonal gastrointestinal disease.
Can pharmaceutical sales data serve as a reliable indicator of disease incidence in India? Examine with reference to over-the-counter purchasing and prescribing practices.
Self-medication for gastrointestinal symptoms is widespread in India. Critically analyse its risks and the role of antibiotic dispensing restrictions in improving drug stewardship.

Grounded only in the source report — figures and dates are the source's, not inferred.

Next storyPremium motorcycles growing over 22%, says TVS official →

← All stories